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a b s t r a c t
Kaposi's sarcoma-associated herpesvirus (KSHV) vOX2 is a cell surface glycoprotein expressed during
viral lytic replication to suppress host inﬂammatory reactions. Here we have characterised vOX2 with
biochemical, biophysical and bioinformatics tools and as a result propose a 3-dimensional model for
vOX2 based on structural and functional homology with the PD-L1 protein. To validate this model, vOX2
was characterised by analytical ultracentrifugation (AUC) and circular dichroism spectroscopy (CD). The
results identiﬁed the potential glycosylation sites and revealed that vOX2 is predominantly a beta-folded
molecule with an RGD adhesion motif exposed on the C-terminal domain. The protein exists in
monomer–dimer equilibrium similar to its IgV-type folded homologues, with 30–36% glycosylation and
the molecular weight of the extracellular fragment of molecule is 32.0–33.6 kDa, much less than 50 kDa.
Thus, the structural similarity to PD-L1 veriﬁes its immunomodulatory potential and the RGD motif
suggests an adhesive capacity.
& 2014 Published by Elsevier Inc.
Introduction
KSHV which belongs to the Herpesviridae, is the aetiological
agent of Kaposi's sarcoma (Chang et al., 1994) and primary effusion
lymphoma (Cesarman et al., 1995; Bouvard et al., 2009). It may
also cause multi-Centric Castle man's disease (Soulier et al., 1995).
Up to one-third of the genome speciﬁes proteins with either
potential or demonstrated immune modulation (Rezaee et al.,
2006; Aresté and Blackbourn, 2009). Open reading frame (ORF)
K14, encodes the vOX2 protein which shares 40% sequence
identity with the mammalian OX2 (now is called CD200) (Foster-
Cuevas et al., 2004). Signal delivery of OX2 occurs through binding
to CD200R (Wright et al., 2000). The distribution of CD200R family
members in humans is more restricted than that of CD200, with
the receptor being expressed on myeloid and T cells (Wright et al.,
2003). Sequentially, these data suggest that the CD200–CD200R
interaction locally modulate inﬂammatory cell activities at the
sites of inﬂammation. In support of these ﬁndings, CD200 has
been identiﬁed as an immuno-regulatory molecule in immune
privileged organs such as CNS which may confer additional
protection against immune destruction through regulation of
macrophage activity. In rodents, antibody-mediated blockade of
CD200R resulted in macrophage activation which was followed by
CNS damage and also aggravated experimental autoimmune
encephalomyelitis (EAE) (Meuth et al., 2008). Activated macro-
phages in CD200-deﬁcient mice, led to rapid onset of EAE (Hoek
et al., 2000). In contrast, elevated neuronal expression of CD200
was followed by reducing EAE pathogenesis (Chitnis et al., 2007).
In humans, CD200 expression in MS lesions and lesion centres was
downregulated which could result in an interrupted balance in
macrophage activation (Koning et al., 2007; Koning et al., 2009).
Furthermore, in SLE patients, CD200R expression was decreased in
CD4þ lymphocytes and DCs; blocking of CD200R by CD200:Fc
resulted in increased CD4þ T-cell proliferation and decreased DCs
migration and Th17 cells differentiation (Li et al., 2012). Also
CD200R expression was shown on mouse and human mast cells,
in these cells, CD200R engagement inhibited mast cell degranula-
tion and decreased IL-13 and TNF secretions (Cherwinski et al.,
2005). From the other point of view, CD200–CD200R signalling
could beneﬁt tumor cells and CD200 gene knockout mice were
resistance to tumor induction; lymph nodes of these mice con-
tained more regulatory T cells which tend to home tumours
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(Rygiel et al., 2012). Moreover, CD200 over-expression in trans-
genic mice could facilitate tumor cell metastasis while neutralising
CD200 could result in decreased metastasis and increased anti-
tumor cytotoxic lymphocytes (Gorczynski et al., 2011).
Since vOX2 like CD200 is a ligand of CD200R (Foster-Cuevas
et al., 2004), the viral protein signalling pathways seem to be like
their cellular counterpart which may inhibit the main components
of immune responses. Previously we constructed engineered form
of vOX2 in which the extracellular domain of the viral protein was
fused with the C-terminal domain of human IgG1 Fc (Rezaee et al.,
2005). Functional studies with a soluble, recombinant form of
vOX2 (vOX2:Fc) revealed that it selectively reduced the oxidative
burst of primary human neutrophils and the production of IL-8 by
rIFN-γ-treated cells of a myeloid lineage cell line to basal levels
(Rezaee et al., 2005). Transfected NK cells and basophil functions
were also down-regulated by vOX2 (Shiratori et al., 2005). How-
ever, vOX2 effects on macrophages have been reported to be both
proinﬂammatory and anti-inﬂammatory depending on microen-
vironment in contradictory studies (Chung et al., 2002; Foster-
Cuevas et al., 2004; Salata et al., 2009). Importantly, by providing
negative costimulatory signal to cytotoxic T cells by vOX2 trans-
fected antigen presenting cells, vOX2 might lead to survival of
KSHV-infected cell; in parallel, CD200 provided a similarly nega-
tive regulatory signal to CTL (Misstear et al., 2012); MHC class I and
class II down-regulation induced by vOX2 (Salata et al., 2009) may
also result in decreased cellular responses, a condition that will
beneﬁt infected cells.
In the present study, PD-L1 was selected as a template to
predict the vOX2 three-dimensional (3D) structure, in order that in
future the functional determinants of vOX2 can be understood.
PD-L1, a type 1 transmembrane protein, is a member of the B7
family (Jin et al., 2011) and also belongs to the Ig-superfamily
(Collins et al., 2005). It is expressed on DCs (Bryant-Hudson and
Carr, 2012), T cells (Channappanavar et al., 2012) and macrophages
(Rodriguez-Garcia et al., 2011). Engagement of PD-L1 to its
receptor, PD-1, which is expressed on T and B lymphocytes
(Agata et al., 1996), negatively regulates T lymphocytes (Freeman
et al., 2000; Carter et al., 2002; Jin et al., 2011; Liechtenstein et al.,
2012). PD-1 pathway could affect broad ranges of immune
responses and exerts signiﬁcant effects in clinical conditions such
as autoimmunity, viral infection and anti-tumor immunity (Jin
et al., 2011). Like PD-L1, vOX2 has negative regulatory activity for
CD8þ T cell (Misstear et al., 2012) and neutrophil function (Rezaee
et al., 2005).
In these studies, vOX2:Fc was expressed from CHO cells as an Fc
fusion protein (Rezaee et al., 2005). We provide the ﬁrst structural
analysis of vOX2 in that regard by reconstructing the predicted
three-dimensional structure of the viral protein on the basis of
biophysical and bioinformatics data.
Results
vOX2 structural model based on its homology with PD-L1
Inspection with PSI-BLAST showed that vOX2 protein has one
IgV like domain between residue 33 and residue 127 (Fig. 1A). This
Ig-like domain contains two cysteine residues at positions 39 and
109 (Fig. 2B), which are predicted to form a disulphide bond. These
data revealed that KSHV vOX2 belongs to the Ig superfamily
molecules.
PD-L1 is a negative regulatory ligand of PD-1 (Jin and Ahmed,
2011; Liechtenstein et al., 2012) that also belongs to the Ig-
superfamily (Collins et al., 2005). Like PD-L1, vOX2 has negative
regulatory activity for CD8þ T cell (Karen Misstear et al., 2012) and
neutrophil function (Rezaee et al., 2005). Since vOX2 has structural
and functional similarities with PD-L1, this molecule (PDB entry:
3FN3) was chosen as the template for modelling of KSHV vOX2.
Regarding these similarities, over 1000 structural models were
generated by MODELLER and 10 structures with the lowest molpdf
score were selected, and their energy minimised by HyperChem.
The most valid model achieved 96.3 ERRAT score (Fig. 1B).
In the present study among 10 energy minimised structures for
vOX2, the best model with high resolution is shown in Fig. 1C. As
ﬁgures show, there are two disulphide bonds, located between
Cys39–Cys109 and Cys148–Cys202 (Figs. 1C-3 and 2B), the ﬁrst but
not the second was predicted by proteomics tools as a critical bond
for formation of Ig-like domains (Wai Wong et al., 2012). Although
the Cys148–Cys202 disulphide bond was not predicted by bioinfor-
matics tools, with considering PD-L1 as a template, it did appear in
all predicted models.
vOX2 is highly glycosylated
In the present study the engineered sequence of vOX2:Fc
encompassing the predicted extracellular (228 amino acid residue)
domain of the viral protein fused in-frame with the Fc component
of IgG1 was considered for bioinformatics analysis. The linker
between the vOX2 and IgG1 Fc domains, contains a proteolytic
Factor Xa enzymatic digestion site (Fig. 3A, lane 3 and lane 4). The
predicted (PeptideMass, ExPASy) size of the vOX2 fragment is
24.6 kDa. However, when constructed vOX2:Fc was cleaved with
Factor Xa, the molecular size of vOX2 in the SDS PAGE gel was
50 kDa (Fig. 3A, lane 1).
The difference between predicted and observed molecular sizes
suggested the possibility of post-translational modiﬁcation of
vOX2, which was more likely to be glycosylation. Using glycosyla-
tion server, six consensus N-glycosylation sites were identiﬁed
within the vOX2:Fc amino acid sequence including Asn83, Asn91,
Asn138, Asn157, Asn166 and Asn321(NetNGlyc, CBS Prediction Ser-
ver). Of these residues, ﬁve are contained within vOX2, and one
(Asn321) is contained within the Fc fragment (Fig. 4A).
In order to determine whether the increased molecular mass of
extracellular domains of vOX2 on SDS PAGE gel was because of
glycosylation, the puriﬁed vOX2 fragment of the Fc fusion protein
was treated with PNGase F, and the deglycosylated bands were
identiﬁed by protein mass ﬁngerprinting technique (James et al.,
1993; Yates et al., 1993). As a result of deglycosylation, the diffuse
band of vOX2 originally migrated at 50 kDa (Fig. 4B, lane 1) shifted
to 25 kDa (Fig. 4B, lanes 2–4), consistent with the predicted
molecular mass of amino acid sequences in bioinformatics analy-
sis. Thus, the results suggest that vOX2 is a highly glycosylated
protein.
To evaluate vOX2 post translation glycosylation, an analytical
ultracentrifugation method was used, since molecular weight of
glycosylated proteins is regularly overestimated by SDS PAGE
(Hames 1982). For this purpose the uncleaved vOX2:Fc construct
was analysed due to its homogeneity in solution (Fig. 5A) with the
values of sedimentation coefﬁcient 6.12 S and molecular weight of
134 kDa. The latter is close to the actual mass expected for Fc
dimer (52.8 kDa) plus dimeric vOX2 (49.2 kDa) together with the
associated carbohydrates attached: two Fc-originated carbohy-
drate chains (3.5 kDa each) and a maximum of 12 carbohydrate
chains of unknown molecular weight on the vOX2 dimer (amount-
ing to 20 kDa of carbohydrates for dimeric vOX2 if the carbohy-
drate chains of vOX2 was assumed to be similar to those on Fc).
The molecular mass of vOX2:Fc in solution was veriﬁed using
sedimentation equilibrium (SE) analysis. SE data were ﬁtted
globally with a single species model (Fig. 5B and C). The resultant
molecular mass of 132710 kDa agrees well with the mass
calculated from its amino acid sequence and that estimated for
the glycosylation. The buoyant mass resulted from SE experiment
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was converted to a molecular mass using a possible range of partial
speciﬁc volumes (v) of 0.59–0.63 ml/g (at 4 1C) for carbohydrates
(Schuster et al., 1994). Since the glycosylation of vOX2 is unknown,
we have determined the buoyant molecular weight of vOX2:Fc, and
as a next step, estimated the contribution of carbohydrates to the
mass of vOX2:Fc, using Eq. (2) as 28% of the total mass. In order to
determine the molecular weight of carbohydrates bound to vOX2
we used this parameter to “deconvolute” vOX2:Fc (employing the
known values for the protein component of vOX2 and Fc and
knowledge of the carbohydrate content for the Fc part (Deisenhofer,
1981). The mass of carbohydrates per vOX2 monomer was calcu-
lated to be between 7.5 kDa and 9 kDa, for plausible carbohyd-
rate v(v of vOX2 will be 0.695 ml/mg). Therefore, the extracellular
domains of glycosylated vOX2 monomer should have a molecular
mass in the range of 32.0–33.6 kDa, corresponding to 30–36% gly-
cosylation.
vOX2 mostly is a beta-stranded protein
The secondary structure of vOX2 was determined experimentally
by CD which refers to the differential absorption of left and right
circularly polarised light. The far UV CD spectrum of vOX2 showed a
strong negative peak between 230 nm and 210 nm with a minimum
at around 218 nm (Fig. 6A) and small positive peak at 196 nm. This
conﬁguration of far UV CD spectrum is typical for that of a protein
with a predominantly β -fold structure (peak 190 and 220 indicate
Fig. 1. vOX2 bioinformatics analysis and homology modelling. (A) The IgV like domain of vOX2 (residue from 33–127) determined by BLAST programme: ohttp://www.ncbi.
nlm.nih.gov/BLAST/4 . The two cysteines at position 39 and 109 are in an appropriate location for disulphide bridging for folding IgV-like domain. (B) The ERRAT plot of the
modelled vOX2 (http://nihserver.mbi.ucla.edu/ERRAT/) with two disulphide-bonds (Cys39–Cys109 and Cys148–Cys202) after energy minimisation. Protein energy minimised
under the molecular mechanic AMBER method (RMS gradient¼0.5) in HyperChem. Misfolded regions are demonstrated by black bar (no black bar in our modelled protein);
error regions between 95% and 99% are shown by grey bars and regions with less error rate for protein folding are indicated by white bars. The most valid model achieved
96.3 ERRAT score. (C) vOX2 homology modelling: extracellular regions of vOX2 modelled by MODELLER9v9 and graphs were created using Accelrys DS Visualizer v2.1. In
these ﬁgures, the glycosyl-linked residues are distinguished by surface (C-1, C-2) and stick (C-3) view. All potential N-glycosylation sites located at Asn 83, 91, 138, 157, 166
and RGD domain (C-1, C-3) at residues 191–193, are exposed on protein surface. 62% of vOX2 is β-sheets with a trace of a α-helix in N-terminal domain of protein. Two
disulphide bonds were predicted between Cys39–Cys109 and Cys148–Cys202; the former has been predicted by proteomics tools as a critical bond for formation of Ig-like
domains while it is controversial for the later; with PD-L1 as a template, Cys148–Cys202 disulphide bond was generated in all predicted models.
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α-helix and β-sheets, respectively). Indeed, the CONTIN procedure
(Provencher and Glockner, 1981) provides secondary structure estima-
tions of 3% α-helix, 38% β-sheet, 24% β-turn and 35% remainder for
such a UV spectrum. These data are consistent with the modelling
data that showed that secondary structure of vOX2 was mainly
(62%) composed of β-strands (Fig. 1C-3).
The near UV CD spectrum displays a broad peak between 270
and 330 nm (Fig. 6B). These data are consistent with the frequency
of aromatic amino acids in the protein, which are present at the
following frequencies: phenylalanine (2.2%), tyrosine (1.4%) and
tryptophan (3.5%) (data are not shown). Tryptophan residues in
folded proteins generally give peaks close to 290 nm; tyrosine and
phenylalanine residues give rise to peaks between 275 and
282 nm and 255 and 270 nm, respectively. This pattern of the
near UV CD spectrum for vOX2 suggests that these aromatic
residues are located in asymmetric environments and are char-
acteristic of the tertiary structure of a folded protein.
vOX2 dimerises in solution
Cleaved vOX2 was examined for the presence of oligomeric
species in solution via SV size-distribution analysis. The distribu-
tion c(s) (Fig. 5A) demonstrates two easily distinguishable peaks
which could be interpreted as both monomeric and dimeric forms
of vOX2 present in solution. The integrated values of sedimenta-
tion coefﬁcient appeared to be lower than calculated s for
spherically shaped particles of correspondent molecular weight:
s20,w
0 for monomeric and dimeric vOX2 was measured as 2.82 S
and 4.6 S respectively, while s (sphere) were estimated as 3.5 S and
5.2 S for monomer and dimer, respectively. This fact implies to
some elongation of vOX2 from spherical shape and, the presence
of carbohydrate chains is also a reason for decrease in the value of
sedimentation coefﬁcient. All examined concentrations of vOX2
were ﬁtted with the value of friction ratio about 2, which reﬂects
the heavy glycosylation of vOX2 molecule. The large difference
between sedimentation coefﬁcients of monomer and dimer sug-
gests “side-to-side” dimerisation.
We applied hydrodynamic bead modelling to the homology model
to validate it against actual experimental results. Thus, the value of
sedimentation coefﬁcient for vOX2 glycosylated monomer calculated
by programme HYDROPRO (Garcia De La Torre et al., 2000) from
atomic coordinates of the homology model was 2.83 S and in excellent
agreement with experimental sedimentation velocity data.
The strength of dimerisation for cleaved vOX2 was determined
with sedimentation equilibrium. The weight-average mass of the
solute was 5573 kDa with v of 0.695 ml/mg as it was determined
above. This value of mass is an intermediate value between molecular
weight of monomeric and dimeric vOX2 (approximately 32 and
64 kDa respectively, as estimated above by de-convolution of the
vOX2:Fc mass). Therefore, the dimer–monomer dissociation model
was applied to ﬁt the data. The experimental SE curves and data ﬁt are
shown in (Fig. 5B and C). As a best-ﬁt result of this data treatment, the
averaged molecular mass for vOX2 monomer was 33.572 kDa
obtained with v of 0.695 ml/mg (at 4 1C) and the dimer–monomer
dissociation constant was 16 μM. The dissociation constant value was
assessed by applying it to the results of the SV experiment. We have
estimated the amount of monomer and dimer in vOX2 samples of
different concentrations used in SV experiment: the equilibrium in the
systemwas displaced towards monomeric species, what was reﬂected









M….P: vOX2 extracellular region 
C....C: Cys39-Cys109 and Cys148-Cys202, disulfide bonds 
E….P: Fcγ1 region 
GR: Factor Xa cleavage site 
RGD: RGD motif 
KSCDKPHTCP: Ig hinge region 
Fig. 2. (A) Schematic ﬁgure illustrating the DNA encoding full length of the KSHV vOX2 protein, V8. (B) The recombinant vOX2:Fc with the extracellular region of vOX2 fused
in to the C-terminal of Fcγ1 (hinge region, Cγ2 and Cγ3). The ExPASy Translate tool (http://www.expasy.org/tools/dna) was used to translate the entire cDNA from compiled
sequence of vOX2:Fc construct in pDR2ΔEF1α.V8:Fc vector into the corresponding amino acid sequence.
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Discussion and conclusions
Since due to very strong adhesive activities, our attempts failed to
reach a reliable structure of vOX2 using X-ray crystallography, the
structural properties of the molecule were determined by biochemical,
bioinformatics and biophysics. The vOX2:Fc protein was produced by
engineered CHO cells as a recombinant Fc-fusion protein. The extra-
cellular region of KSHV vOX2 fused to the CH2, CH3 domains and
hinge region of Fc fragment of human IgG1 (Fig. 2B). The construction
of fusion proteins enables the generation of recombinant proteins for
structural, functional and therapeutic studies.
The extracellular region of KSHV vOX2 (aa 1–230) is glycosylated,
since the protein contains at least ﬁve potential N-glycosylation sites,
which confer an electrophoretic mobility of around 50 kDa (Fig. 3A,
lanes 2, and C lane 2). Consistent with this post-translational
modiﬁcation, the 228 amino acids extracellular region of the protein
predicted has a molecular weight of 24.6 kDa, calculated by bioinfor-
matics servers from the known amino acid sequence. This ﬁnding also
strongly suggested that vOX2 is highly glycosylated. Apparently,
according to this study and other researchers, the full protein
molecular weight containing intracellular region is approximately
55 kDa (Chung et al., 2002). Deglycosylation of extracellular regions of
protein showed that molecular weight reduced from 50 to 25 kDa
(Fig. 4B, lanes 2–4). Therefore, the molecular weight of oligosacchar-
ide chains seems to be around 25 kDa or 100% increase in protein
weight which is not rational for a glycoprotein. However, in the
present study, considering bioinformatical model and predicted
glycosylation sites along with biophysical analysis revealed that the
glycosylated vOX2 should have a molecular mass of 32.0–33.6 kDa,
corresponding to 30–36% glycosylation. This number is comparable to
other glycosylated proteins participating in the immunological
response such as CD80 family (Fairman et al., 1999).
In our suggested model, high ERRAT score (96.3%) besides ﬁne
matching of bioinformatical and biophysical data, could provide
more conﬁdence on accuracy of bioinformatically determined
three-dimensional model and infers that PD-L1 selection as a tem-
plate is satisfactory. In addition, both vOX2 and PD-L1 structures
are mainly composed of beta sheets and belong to Ig superfamily.
Their biological functions are similar; like vOX2, PD-L1 engage-
ment is followed by negative regulation of immune system
(Freeman et al., 2000; Carter et al., 2002; Jin et al., 2011;
Liechtenstein et al., 2012).
The extracellular region of the vOX2 most likely represents the
biologically important region of vOX2 through binding to the
CD200-R1 (Foster-Cuevas et al., 2004). The cytoplasmic region of
the vOX2 lacks sequence identity with known signalling motifs, or
typical docking sites for adaptor molecules (NCBI. BLAST and
MotifScan programmes).
Initial analyses of vOX2 suggested that the N-terminal region of
the molecule has 45% similarity with IgV-like domain and protein
has an integrin-binding motif, RGD, at residues 191–193, C-terminal
(Fig. 1C-3 and Fig. 2B). The protein has no other sequence identity
with other known protein motifs (NCBI. BLAST).
The PSI-BLAST analysis of vOX2 (in NCBI) also showed structural
similarities with number of cell adhesion glycoproteins such as
Nectin-1, Down Syndrome Cell Adhesion Molecule (Dscam) and
Fig. 3. Cleavage of vOX2:Fc fusion protein with factor Xa and protein puriﬁcation. The linker region of vOX2:Fc fusion sequence contains a factor Xa cleavage site which is an
appropriate point for removing the Fc tag by the Factor Xa Cleavage Capture Kit (Novagen). After treatment of the vOX2:Fc protein, Factor Xa is removed from the reaction by
afﬁnity capture on Xarrest Agarose, and cleaved vOX2 and Fc fragments were puriﬁed with a protein A column. The wash contains cleaved vOX2, and uncleaved vOX2:Fc and
Fc tag was then eluted with 0.1 M citrate, pH 3.0. The protein and protein fractions contained in the column wash and elute were checked by SDS-PAGE under reducing and
denaturing condition with Coomassie Blue staining (A), or western blot using anti-human IgG-HRP (B), or a mixture of anti-vOX2 monoclonal antibodies (C). (A) Coomassie
Blue staining: Lane 1, vOX2 post digest, post Xarrest; Lane 2, protein A column wash (vOX2); Lane 3, vOX2:Fc pre-factor Xa digestion; Lane 4, vOX2:Fc post factor Xa
digestion, pre-Xarrest. (B) Immunoblot using anti-human IgG-HRP: Lane 1, vOX2:Fc predigest; Lane 2, protein A column wash (vOX2); Lane 3, vOX2:Fc predigest (overload);
Lane 4, vOX2 post digest, pre Xarrest; Lane 5 vOX2 post digest, post Xarrest, Lane 6, protein A elution (Fcþcontaminants). (C) Immunoblot using anti-vOX2 mAbs: Lane 1,
vOX2:Fc predigest; Lane 2, protein A columnwash (vOX2); Lane 3, vOX2:Fc predigest (overload); Lane 4, vOX2 post digest, pre Xarrest; Lane 5 vOX2 post digest, post Xarrest,
and Lane 6, protein A elution (Fcþcontaminants). (D) Culture supernatants of CHO vOX2:Fc cell line were puriﬁed by protein A afﬁnity chromatography (HiTrap column) and
polished on HiLoad 16/60 Superdex 200 prep grade column. The positions of the proteins are indicated by the arrows, after their identities were conﬁrmed by MALDI-TOF
and tandem MS (from protein A puriﬁed protein). n: Two regions of this diffuse single band were analysed by MS. Fusion proteins were detected by western blot with anti-
human IgG-HRP antibody in reducing conditions and visualised with ECL blotting reagents. The 30 and 50 kDa bands are products of Fc-fusion protein degradation. The
molecular size markers (kDa) are shown at the left of the gel and the blots.
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NCAM. Because of structural similarity between vOX2 and proteins
involved in cell adhesion, it used to refer to vNCAM or v-adh, which
indicated its probable roll in cell to cell adhesion. In addition to
structural similarity, the KSHV vOX2 protein has an RGD tri-peptide
motif. In some proteins for instance, vitronectin, ﬁbrinogen and
Latency Associated Peptide (LAP) complex of TGF-β (Barczyk et al.,
2010), this motif participates in receptor interactions by binding to
integrins. For example, the major integrin-binding site of NCAM lies
on a segment of domain Ig6 that includes a RGD motif, which is
recognised by integrins such as αv, two β1 integrins (α5 and α8) and
αIIbβ3 (Chen and Chen, 2011; Sutherland et al., 2012). Initially, KSHV
vOX2 was speculated to be an adhesion molecule (vadh) (Russo et al.,
1996) and a suggested homologue of NCAM. The existence of an RGD
motif in vOX2 raises the possibility that the viral protein participates
in cell adhesion. However, no such motif is present in CD200. This
possibility was conﬁrmed by dendritic cells (DCs) aggregation
induced by vOX2 treatment (Chung et al., 2002) and our ﬁnding
showed the same effect, vOX2-transfected Jurkat cells form large
aggregate (data not shown). Moreover, as a homologue of CD200, it
may participate in cell–cell contact in the site of the immunological
synapse, particularly the monocyte/macrophage-tissue and APC-T
cell synapses (Rezaee et al., 2006).
In the present study, our bioinformatics modelling results
demonstrated that the RGD motif is exposed on the C-terminal
domain of the protein surface. Furthermore, our data showed that
vOX2 could form “side-to-side” dimers which could propound a
possibility: homophilic binding between two adjacent cells by
dimerising vOX2 molecules present on cell surface, like NCAMs
(Rao et al., 1993; Sandig et al., 1994). The homophilic interaction
between NCAMs on adjacent cells appears in some instances and
requires the presence of heparan sulphate as a co-receptor (Cole
et al., 1986). In addition to homophilic binding, vOX2 participates
in heterophilic binding, in which vOX2 binds to a counter-receptor,
CD200Rs, present on the cells of immune system. However, further
studies are required to determine whether this motif and “side-to-
side” dimerisation in vOX2 participate in cell contact.
vOX2 shares identity with the CD200 (Foster-Cuevas et al., 2004).
The role of cellular CD200 is modulation of the activities of myeloid
lineage cells, perhaps via costimulatory signal alteration. Cellular CD200
protein belongs to a group of leucocyte Ig super-family glycoproteins
including NCAM and Thy-1, which is generally expressed in both
lymphoid and neuronal tissues (Clark et al., 1985). CD200 contributes
to various activities that NCAM also inﬂuences, for example, morpho-
genesis, neural development (Morris and Beech, 1987), neuronal cell to
Fig. 4. vOX2 N-glycosylation analysis. (A): The predicted N-glycosylation sites of the vOX2:Fc fusion protein sequence were determined using the NetNGlyc 1.0 Server (http://
www.cbs.dtu.dk/services/NetNGlyc/). This glycoprotein contains six potential N-glycosylation sites located at Asn 83, 91, 138, 157, 166 and 321. As indicated in the ﬁgure, of
the six residues, ﬁve were identiﬁed in the extracellular region of vOX2 (N1-N5), and only one in the Fc fragment of the recombinant protein (N6). (B): The vOX2 fusion
protein was treated with increasing amounts of PNGase F. After treatment, the protein was analysed by SDS-PAGE under reducing and denaturing conditions and stained
with Coomassie Blue to reveal the diffuse band of vOX2 that originally migrated as a molecular mass of 50 kDa shifted to a molecular mass of 25 kDa consistent with that of
the predicted molecular mass of the protein lacking glycosylation. Lane 1, denatured vOX2þwater; Lane 2, denatured vOX2þ0.25 units PNGase; Lane 3, denatured
vOX2þ2.5 units PNGase, and Lane 4, denatured vOX2þ5 units PNGase. The molecular size markers (kDa) are shown at the left of the gel and the blots.
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cell interaction and growth of dendrites and axons (Bartolome et al.,
2002). Thus, CD200 and NCAM could act as complementary glycopro-
teins during the development and organisation of the nervous system.
Moreover, CD200 has been identiﬁed as an immunoregulatory mole-
cule in immune privileged organs such as the CNS (Koning et al., 2009)
and eye (Broderick et al., 2002). The immune status of the CNS and eye
is strictly regulated and responses are kept to a minimum. In contrast,
the distribution of CD200 receptor family in human is more restricted
to myeloid and T cells (Wright et al., 2003) than that of CD200,
suggesting the CD200/CD200R interaction acts locally to modulate
inﬂammatory-cell activity at sites of tissue damage. Overall, vOX2 in
KSHV may also provide an immunological privilege site for the virus to
escape from host immune responses.
Functional studies with the puriﬁed vOX2:Fc protein in vitro
revealed that it speciﬁcally reduced the oxidative burst of primary
human neutrophils and the production of IL-8 by rIFN-γ-treated
myeloid cell line to basal levels (Rezaee et al., 2005) and also
suppressed phosphorylation of ERK1/2 MAP kinase in T cells which
was followed by reduced speciﬁc T cell responses (Karen Misstear et
al., 2012). Therefore, besides Ig superfamily structure, it functionally
belongs to the B7 family of accessory molecules such as CD80, CD86
and PD-L1. Among B7 family members, bioinformatics studies showed
that structural and functional properties of PD-L1 made it a good
candidate to be used as a template to model KSHV vOX2. Alongside
with their structural similarity, biophysical and functional activities
of these two proteins are comparable. Like vOX2/CD200R1 weak
engagement, PD-L1 and PD-1 interaction is much weaker than
expected which might result in weak PD-1/PD-L1 complex (Cheng
et al., 2013). Engagement of PD-L1 to its receptor, PD-1, negatively
regulates T lymphocytes (Freeman et al., 2000; Carter et al., 2002; Jin
et al., 2011; Liechtenstein et al., 2012). PD-1 pathway could affect broad
ranges of immune responses and exerts signiﬁcant effects in clinical
conditions such as autoimmunity, viral infection and anti-tumor
immunity (Jin et al., 2011). Blockade of PD-1/PD-L1 interaction might
have therapeutic application and recently has been used in patients
with advanced haematologic malignancies with remarkable results
(Berger et al., 2008). Like PD-L1, vOX2 can provide negative regulatory
signals for modulating of immune responses, particularly monocyte/
macrophage (Foster-Cuevas et al., 2004), CD8þ T cell (Misstear et al.,
2012) and neutrophil function (Rezaee et al., 2005).
In conclusion, our analyses revealed that vOX2 exists in mono-
mer–dimer equilibrium and is composed predominantly of beta-
sheets with a putative integrin-binding RGD motif, exposed on the
C-terminal of the molecule. The molecular weight of extracellular
Fig. 5. The results of sedimentation velocity (A) and sedimentation equilibriums (B and C) for both Fc-tagged and cleaved vOX2 samples. Sedimentation velocity (SV) and
sedimentation equilibrium (SE) experiments were carried out on a Beckman Coulter (Palo Alto, CA, USA) Optima XL-I analytical ultracentrifuge using both absorbance at
280 nm and interference optics. The experimental temperature for all AUC runs was 4 1C. The sample volume was 100 and 400 μM for SE and SV, respectively; the sample
concentrations were ranged between 0.09 and 1 mg/ml. (A) Comparative SV characterisation of vOX2:Fc and vOX2. Insets: the concentration dependence of the weight-
average sedimentation coefﬁcient obtained by integration of c(s) distribution; the sedimentation coefﬁcients calculated for glycosylated monomer (sphere) and glycosylated
dimer (two spheres) are indicated by arrows; c(s) distribution of vOX2:Fc in solution is shown at 45,000 rpm (interference data), and c(s) distribution of vOX2 in solution is
shown at 48,000 rpm (absorbance data). (B) Sedimentation equilibrium (SE) data obtained at 11,500 rpm and 15,000 rpm, c¼0.35 mg/ml were ﬁt to single species model;
(C) SE data obtained at 25,000 rpm; the data were ﬁt to monomer-dimer association model.
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domains of vOX2 is much less than expected 50 kDa, as observed
in SDS PAGE, and is 32.0–33.6 kDa in which by considering 5 kDa
transmembrane region and intracellular tail, molecular weight of
complete protein will be 37.0–38.6 kDa. Taking together, the
bioinformatics, biochemical and our previous results indicate that
KSHV vOX2 due to similarity to PD-L1, high adhesive properties
and implication of its cellular homolog (CD200) in neurogenesis,
might be considered as an adhesive immunomodulatory protein of
Ig superfamily molecules, particularly immune-inhibitory mem-
bers of B7 family. However, due to the controversial functions of
KSHV vOX2 and its cellular counterpart CD200, it needs more
studies to validate the biological activities of these molecules.
Materials and methods
Bioinformatics
The amino acid sequence of vOX2 was analysed using PROSITE
(http://prosite.expasy.org/) and NetNGlyc 1.0 tools (http://www.
cbs.dtu.dk/services/NetNGlyc/) in order to reveal folding patterns
peculiar to vOX2 amino acid sequence and identify N-glycosylation
sites, respectively.
Water-soluble vOX2 has 231 amino acids broadly consisting
of two domains: an N-terminal domain including IgV-like fold-
ing pattern recognised by PSI-BLAST (the residues 1–130) and
C-terminal domain (the residues 131–231). Position-Speciﬁc Itera-
tive Basic Local Alignment Search Tool (PSI-BLAST) derives a
position-speciﬁc scoring matrix (PSSM) or proﬁle from the multi-
ple sequence alignment of sequences detected above a given score
threshold using protein–protein BLAST (Bhagwat, 2007). Three-
dimensional models of the vOX2 sequences were constructed by
homology modelling. BLAST sequence homology searches were
performed in order to identify the template proteins by PSI-BLAST
(http://www.ncbi.nlm.nih.gov/BLAST/) (Altschul et al., 1997)). Mul-
tiple alignments were carried out on the selected sequences by
ClustalX2 (protein weight matrix: BLOSUM series). For this align-
ment analysis, the 24 amino acid signal peptide was removed.
Protein modelling was performed by MODELLER9v9 (http://salilab.
org/modeller/). In MODELLER, predicted structures were assigned
a molecular probability density function (molpdf) score based on
the sum of all restraints. By molpdf, models could be ranked from
the same alignment; lower molpdf means the restraints are better
satisﬁed and gains better score in model validation. Structure
reﬁnements and energy minimisation performed by a Hyper
Chem7.5 (Hypercube Inc., http://www.hyper.com/) under a mole-
cular mechanic AMBER method (RMS gradient¼0.5). All models
were validated using the programme ERRAT (Colovos and Yeates,
1993) (UCLA, http://nihserver.mbi.ucla.edu/savs/). ERRAT has an
“Overall quality factor” ranging from 0 to 100. Acceptable scores
depend on protein size and models with better quality (less error
prone regions) gaining higher scores.
Construction of expression vectors
Sequences encoding the extracellular region of KSHV vOX2
gene (V8) (Fig. 2A) were PCR ampliﬁed. The gene was cloned from
the BC-1 KSHV-infected PEL cell line (Cesarman et al., 1995) into
the pCR2.1 TA cloning vector, where the sequence was veriﬁed,
then subcloned into an expression vector. The gene was ampliﬁed
using Platinum Pfx (Invitrogen, Paisley, Scotland) with the relevant
primers as follows: sense, 50–GCT CTA GAT GTC TAG CCT CTT CAT
TTC ATT AC-30; antisense, 50–TAT GCG GCC GCG GCC GCG GGA AGG
TCA TGG GC-30. These ampliﬁcation primers included restriction
sites (Xba I and Not I) enabling subcloning of the gene into the
expression vector. Sequencing of both strands of the V8 gene in
both directions conﬁrmed that no errors had been introduced by
PCR. After sequencing, V8 gene was subcloned into the pDR2Δ
EF1α.Fc expression vector (see (Charreau et al., 1994; Spiller et al.,
2003) to create pDR2ΔEF1α.V8:Fc expression vectors in which the
vOX2 gene was cloned upstream and in frame of the Fc fragment
of IgG1. Subcloning involved digestion of the V8 insert from
pCR2.1-TOPO constructs with Xba I and Not I and ligation into
Spe I and Not I digested pDR2ΔEF1α.Fc. Expression plasmid was
then sequenced over the sites at which the V8 DNA fragments
were cloned to ensure that the ligation had generated an in-frame
fusion of the viral and IgG1 Fc genes.
Cell transfection
Chinese hamster ovary cells (CHO) were transfected with a
Lipofectamine (Invitrogen, Paisley, Scotland) method. Transfection
was carried out by incubating the cells at 50% conﬂuency
(7105cells) overnight prior to transfection in 60 mm dishes. On
the day of transfection, the puriﬁed DNA (25 ng in 100 μl serum
free medium) was mixed with Lipofectamine mixture (5 μl Lipo-
fectamine with 95 μl serum free medium) and incubated at room
Fig. 6. Far UV (A ) and near UV (B) circular dichroism spectra for cleaved vOX2 at
0.2 mg/ml in phosphate buffer (91.5 mM Na2HPO4, 58.5 mM NaH2PO4, pH 7.4). The data
were best ﬁtted with 3% alpha-helix, 38% beta-sheet, 24% beta-turn and 35% other.
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temperature for 45 mins. Then 0.8 ml serum free medium was
added to the DNA-lipofectamine mixture and plated onto the cells
and incubated at 37 1C for 5 h. Medium containing DNA was then
removed and, 1 ml antibiotic free, 20% serum medium was added.
After transfection (72 h post addition of DNA), the medium was
replaced with selective medium containing 400 μg ml1 Hygromy-
cin B. This minimal concentration of Hygromycin B required to kill
untransfected cells, was determined by performing a dose response
analysis. Following selection, cells transfected with pDR2EF1α were
maintained with Hygromycin B (100 μg ml1).
Protein puriﬁcation
vOX2:Fc transfected CHO cells cultured in RPMI-1640 were
supplemented with 4% FCS, Glutamine (2 mM), Ampicillin/strep-
tomycin (100 IU/ml and 100μg/ml, respectively) and non-essential
amino acids (100 μM). Cell culture supernatants were stored at
4 1C until the volume exceeded 2 l. In the current study an
automated two-step puriﬁcation method (AKTA protein puriﬁer
system, Amersham) for the Fc fusion protein was chosen based on
capture by afﬁnity chromatography, followed by “polishing” with
gel ﬁltration. Afﬁnity chromatography on HiTrap recombinant
protein A was chosen for its high selectivity for IgG1. Suitable
conditions for binding and elution buffers were optimised, in
which a two-step elution system was selected. In the ﬁrst step,
to remove low afﬁnity molecules such as bovine Ig, a 0.1 M sodium
citrate buffer (pH 5.0) was used, and in the next step a 0.1 M
glycine/HCl buffer (pH 3.0) elution buffer was selected. Immedi-
ately to neutralise the low pH and prevent protein degradation,
Tris buffer (pH 9.0) was added to collected proteins. To remove low
or trace levels of contaminants, such as aggregates and degraded
fragments including truncated vOX2:Fc and Fc protein fragments,
the proteins were ‘polished’ by gel ﬁltration on a HiLoad 16/60
Superdex 200 size exclusion column.
Protein purity
All puriﬁed protein fractions were examined by SDS-PAGE gel
and Western Blot detection with anti-human IgG-HRP. Identity
was conﬁrmed by MALDI-TOF and tandem MS (from protein A
puriﬁed protein). The concentration of cleaved vOX2 and vOX2:Fc
was determined by absorbance spectroscopy at 280 nm using an
extinction coefﬁcient (ε) of 2.05 cm2 mg1 and 1.65 cm2 mg1
respectively; these values were calculated from the amino acid
sequences of the proteins. The protein concentration was also
assayed by Bradford assay (Bradford, 1976).
Fc-tag removal
The Fc component of human IgG1 was removed from recombi-
nant vOX2:Fc with Factor Xa enzyme (Novagen). A linker region
placed between the vOX2 fragment and the Fc tag of the vOX2:Fc
fusion sequence contains a factor Xa cleavage site. vOX2:Fc fusion
protein was cleaved using an Xarrest™ Agarose kit (Novagen)
according to the manufacturer’s instruction. After cleavage, Factor
Xa was removed from the reaction by afﬁnity capture on. To purify
cleaved vOX2 and Fc, the post-Xarrest solution (protease-free) is
then loaded onto the protein A column and washed with the
equilibration/loading buffer. The protein fractions were checked by
SDS-PAGE under reducing conditions with Coomassie Blue stain-
ing and Western Blot, using anti-vOX2 monoclonal antibodies and
anti-human IgG-HRP. The identity of bands in the Coomassie Blue
stained gel was then conﬁrmed with tryptic mass spectrometry
(MALDI- TOFF).
vOX2 protein deglycosylation
Deglycosylation was carried out using a PNGase F kit (NEB, UK),
according to manufacturer's instruction, brieﬂy. The puriﬁed vOX2
fragment of the vOX2:Fc fusion protein was introduced to 0.25,
2.5 and 5 units of PNGase F under denaturing condition. 10 mg of
protein was combined with denaturing buffer and distilled water
to make a 10 μl total reaction volume, heated at 100 1C for 10 min.
Then PNGase F with other additives incubated for 60 min at 37 1C.
After the treatment, normal and deglycosylated proteins were
introduced to Coomassie Blue staining of SDS-PAGE under redu-
cing and denaturing conditions.
Circular dichroism spectroscopy
Circular dichroism (CD) spectra of cleaved vOX2 were recorded
at 20 1C using a JASCO J-600 spectropolarimeter (JASCO UK Ltd.,
UK). The far ultra violet (UV) CD spectrum (260–190 nm) of vOX2
was measured using a 0.02 cm path length quartz cell at the speed
of 50 nm/min and response 0.5 s, 8 scans were taken. The near UV
CD spectrum (320–260 nm) of vOX2 was obtained in 0.2 cm path
length quartz cell at the speed of 20 nm/min and response 1 s,
4 scans were taken. The protein concentration was 0.2 mg/ml in
phosphate buffer (91.5 mM Na2HPO4, 58.5 mM NaH2PO4, pH 7.4).
Secondary structure estimations were obtained using the Pro-
vencher and Glockner method (Provencher and Glockner, 1981).
Analytical ultracentrifugation (AUC)
Sedimentation velocity (SV) and sedimentation equilibrium
(SE) experiments were carried out on a Beckman Coulter (Palo
Alto, CA, USA) Optima XL-I analytical ultracentrifuge using both
absorbance at 280 nm and interference optics. The experimental
temperature for all AUC runs was 4 1C. The sample volume was
100 μl and 400 μM for SE and SV respectively, and the sample
concentrations were ranged between 0.09 and 1 mg/ml. SV
experiments were carried out at rotation speed of 45,000 and
48,000 rpm for vOX2:Fc construct and cleaved vOX2 respectively.
Partial speciﬁc volumes (v) for the protein part of vOX2 itself and
vOX2:Fc were calculated from the protein amino acid sequence,
using the programme SEDNTERP (Laue et al., 1992) and extra-
polated to the experimental temperature following the method of
Durchschlag (Durchschlag, 1986). The contribution of carbohy-
drate part in molecular weight of Fc-tag was estimated using
following formula (Durchschlag, 1986). Both density and viscosity
of PBS buffer at the experimental temperature were calculated
using SEDNTERP. Sedimentation velocity proﬁles were treated
using size-distribution c(s) model implemented in the programme
SEDFIT (Schuck, 2000). In order to determine the mass of each
species, the c(s) distribution was converted to c(M) distribution.
Each peak on the distribution plot was integrated in order to
obtain the weight-averaged values for sedimentation coefﬁcient
and molecular mass. Integrated values of sedimentation coefﬁcient
(s) obtained at experimental conditions were converted to the
standard conditions (s20,w) (which is the value of sedimentation
coefﬁcient in water at 20 1C).
Equilibrium in SE experiments was attained after 45 h. SE
traces for vOX2:Fc were obtained at 11,500 15,000 and
25,000 rpm. True optical baselines were obtained after a further
6 h of rotation at 48,000 rpm. SE data were ﬁtted globally using
both the Beckman XL-A-XL-I software implemented in Microcal
ORIGIN 6.0 and the NONLIN programme (Johnson et al., 1981)
(WINDOWS version). The “fringe extinction coefﬁcient” N derived
from SV data was used to convert the association constant in
inverse fringe units to a dissociation constant in molar units. The
molecular weight of glycosylated vOX2:Fc was estimated using
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where Mexpbuoyant ¼Mð1vρÞis determined experimentally via SE
experiment, Mcalculatedprotein is molecular mass of the protein calculated
from its amino acid sequence, vp and vcarbohydr are partial speciﬁc
volumes for protein and carbohydrate components respectively, ρ
is the density of solvent. The carbohydrate content (%) of glycosy-
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